MILK AND PLASMA-CONCENTRATIONS OF THE PROGESTIN-ST-1435 IN WOMEN TREATED PARENTERALLY WITH ST-1435

被引：20

作者：

LAHTEENMAKI, PLA ^{[1
]}

DIAZ, S ^{[1
]}

MIRANDA, P ^{[1
]}

CROXATTO, H ^{[1
]}

LAHTEENMAKI, P ^{[1
]}

机构：

[1] INST CHILENO MED REPROD,SANTIAGO,CHILE

来源：

CONTRACEPTION | 1990年 / 42卷 / 05期

基金：

美国安德鲁·梅隆基金会;

关键词：

D O I：

10.1016/0010-7824(90)90082-7

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

A subcutaneous contraceptive capsule releasing progestin ST-1435 was used by 6 breast-feeding women. One to three paired milk and plasma samples were collected over a one-month period and the concentrations of ST-1435 were determined by radioimmunoassay. An improved and sensitive method for determination of ST-1435 in milk was developed. A column chromatographic purification of milk prior to radioimmunoassay decreased the blank and improved sensitivity. The average plasma concentration of ST-1435 was 62 ± 20 pg/ml (mean ± SD). The average milk concentration of ST-1435 was 38 pg/ml (ranging from 7 to 73 pg/ml), while the average milk to plasma ratio was 0.60 (ranging from 0.25 to 0.91). There was a significant correlation between ST-1435 concentrations in breast milk and plasma, indicating that the concentration in plasma is the major determinant for the amount of ST-1435 excreted into milk. Since studies with this drug have shown good contraceptive efficacy and low bioavailability after oral intake, ST-1435 is a good candidate for lactational contraception. © 1990.

引用

页码：555 / 562

页数：8

共 16 条

[11] SERUM NON-PROTEIN BOUND PERCENTAGE AND DISTRIBUTION OF THE PROGESTIN-ST-1435 - NO EFFECT OF ST-1435 TREATMENT ON PLASMA SHBG AND CBG BINDING-CAPACITIES [J].